13F reference period
Q2 2026
Security Snapshot
Nurix Therapeutics, Inc. - COMMON STOCK (NRIX) Institutional Ownership
CUSIP: 67080M103
13F Institutional Holders and Ownership History from Q3 2020 to Q3 2026
Institutions Reporting
211
Shares (Excl. Options)
117.26M
Full value: 117,256,617 · shares · 30 Jun 2026Price
$24.26
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / COMMON STOCK
- Symbol
- NRIX on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 117,256,617
- Total 13F value
- $2,843,637,346
- Portfolio coverage rank
- 0%
- Share change
- +107,395
- Value change
- +$51,554,724
- Number of holders
- 211
- Shares outstanding
- 103,585,629
- SEC-reported price per share
- $23.71
- Insider filing price
- $23.71
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- NRIX - Nurix Therapeutics, Inc. - COMMON STOCK is tracked under CUSIP 67080M103.
- 211 institutions reported positions in Q2 2026.
- 12 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 195 to 211 between Q1 2026 and Q2 2026.
- SEC-reported value moved from to
$1.81B
Full value: $1,814,188,220 · USD · 31 Mar 2026.$2.84B
Full value: $2,843,637,346 · USD · 30 Jun 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 211 institutions filings for Q2 2026.
Security key
67080M103
13F reference period
Q2 2026
13F holders
211
13D/G owners
12
CIK / CUSIP context first
Open Q2 2026 holders
NRIX full holder history
Nurix Therapeutics, Inc. SEC filings
Nurix Therapeutics, Inc. company facts
Nurix Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 67080M103:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
12
Security
NRIX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Redmile Group, LLC | 8.1% | -18% | $210,510,676 | -$45,879,970 | 8,782,256 | -18% | Redmile Group, LLC | 30 Jun 2026 |
| Vestal Point Capital, LP | 7.8% | +25% | $192,958,500 | +$37,153,500 | 8,050,000 | +24% | Vestal Point Capital, LP | 30 Jun 2026 |
| Deep Track Capital, LP | 7.4% | +21% | $185,442,826 | +$33,347,328 | 7,736,455 | +22% | Deep Track Capital, LP | 30 Jun 2026 |
| BAKER BROS. ADVISORS LP | 7.2% | $138,364,566 | 7,527,996 | Baker Bros. Advisors LP | 31 Dec 2025 | |||
| Rubric Capital Management LP | 7% | $173,249,839 | 7,227,778 | Rubric Capital Management LP | 30 Jun 2026 | |||
| BlackRock, Inc. | 8.2% | $72,644,381 | 6,284,116 | BlackRock, Inc. | 31 Mar 2025 | |||
| PERCEPTIVE ADVISORS LLC | 5.3% | $149,765,814 | 5,536,629 | Perceptive Advisors LLC | 16 Sep 2026 | |||
| PRICE T ROWE ASSOCIATES INC /MD/ | 5.3% | $130,314,990 | 5,436,587 | T. Rowe Price Associates, Inc. | 30 Jun 2026 | |||
| VANGUARD CAPITAL MANAGEMENT LLC | 5% | $124,692,539 | 5,202,025 | Vanguard Capital Management | 30 Jun 2026 | |||
| FMR LLC | 4.2% | -24% | $103,152,641 | -$28,230,904 | 4,350,596 | -21% | FMR LLC | 30 Sep 2026 |
| Commodore Capital LP | 4.9% | -4% | $34,927,708 | -$646,292 | 3,780,055 | -1.8% | Commodore Capital LP | 30 Sep 2025 |
| WELLINGTON MANAGEMENT GROUP LLP | 4.2% | $36,861,858 | 3,188,742 | Wellington Management Group LLP | 31 Mar 2025 |
As of 30 Jun 2026,
211
institutional investors reported holding
shares of
Nurix Therapeutics, Inc. - COMMON STOCK (NRIX).
This represents
113%
of the company’s total
outstanding shares.
117.26M
Full value: 117,256,617 · shares · 30 Jun 2026103.59M
Full value: 103,585,629 · shares · Stored outstanding share count13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
89%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | 8.5% | 8,770,349 | -1.7% | 0% | $212,768,666 |
| Vestal Point Capital, LP | 7.8% | 8,050,000 | +24% | 4.6% | $195,293,000 |
| Deep Track Capital, LP | 7.5% | 7,736,455 | +22% | 2.8% | $187,686,398 |
| Rubric Capital Management LP | 7% | 7,227,778 | +192% | 1.6% | $175,345,894 |
| FMR LLC | 5.3% | 5,485,215 | -1% | 0.01% | $133,071,325 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 5.2% | 5,436,587 | +65% | 0.01% | $131,892,000 |
| MORGAN STANLEY | 4.6% | 4,762,484 | -3.4% | 0.01% | $115,537,879 |
| STATE STREET CORP | 4.5% | 4,677,244 | -9% | 0% | $113,469,939 |
| BAKER BROS. ADVISORS LP | 4.5% | 4,658,556 | 0% | 0.57% | $113,016,569 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.3% | 4,495,529 | +1.5% | 0% | $109,061,534 |
| PERCEPTIVE ADVISORS LLC | 4.2% | 4,320,422 | +16% | 1.6% | $104,813,438 |
| Redmile Group, LLC | 3.9% | 4,073,787 | -47% | 6.6% | $98,830,073 |
| GENERAL ATLANTIC, L.P. | 2.9% | 3,032,185 | -26% | 2.5% | $73,560,808 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.4% | 2,537,291 | +0.68% | 0% | $61,566,526 |
| Pictet Asset Management Holding SA | 2.3% | 2,351,232 | -14% | 0.05% | $57,040,888 |
| ARK Investment Management LLC | 1.7% | 1,793,196 | +4.2% | 0.28% | $43,502,930 |
| Capital World Investors | 1.7% | 1,787,916 | +100% | 0.01% | $43,374,842 |
| Trails Edge Capital Partners, LP | 1.5% | 1,573,220 | -9.8% | 6.1% | $38,166,318 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1.4% | 1,482,861 | +35% | 0% | $35,974,208 |
| CITADEL ADVISORS LLC | 1.4% | 1,477,019 | +9.9% | 0.02% | $35,832,481 |
| Soleus Capital Management, L.P. | 1.4% | 1,465,163 | +56% | 1.2% | $35,544,854 |
| DIMENSIONAL FUND ADVISORS LP | 1.4% | 1,431,317 | +83% | 0.01% | $34,720,069 |
| EVENTIDE ASSET MANAGEMENT, LLC | 1.3% | 1,297,893 | 0% | 0.42% | $31,486,884 |
| BRAIDWELL LP | 1.2% | 1,286,769 | -27% | 1.2% | $31,217,016 |
| Kynam Capital Management, LP | 1.2% | 1,194,757 | 0% | 1.6% | $28,984,805 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
25
Headline period
Q2 2026
Rows shown
1-25 of 25
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 4,323,419 | $102,533,654 | -$41,283,120 | $23.71 | 42 |
| 2026 Q2 | 117,256,617 | $2,843,637,346 | +$51,554,724 | $24.26 | 211 |
| 2026 Q1 | 117,046,410 | $1,814,188,220 | +$39,874,344 | $15.50 | 195 |
| 2025 Q4 | 113,423,406 | $2,151,627,911 | +$525,564,750 | $18.97 | 182 |
| 2025 Q3 | 84,776,704 | $783,330,709 | -$36,480,592 | $9.24 | 171 |
| 2025 Q2 | 88,319,847 | $1,005,944,844 | +$40,932,248 | $11.39 | 161 |
| 2025 Q1 | 84,604,598 | $1,005,122,777 | +$28,667,924 | $11.88 | 168 |
| 2024 Q4 | 81,104,522 | $1,528,053,172 | +$225,677,197 | $18.84 | 173 |
| 2024 Q3 | 67,877,304 | $1,525,459,447 | +$59,100,303 | $22.47 | 170 |
| 2024 Q2 | 64,996,165 | $1,356,466,249 | +$340,051,233 | $20.87 | 172 |
| 2024 Q1 | 49,045,600 | $720,957,554 | +$50,639,301 | $14.70 | 138 |
| 2023 Q4 | 46,078,653 | $475,525,962 | +$17,732,104 | $10.32 | 127 |
| 2023 Q3 | 44,845,094 | $352,482,854 | +$8,466,362 | $7.86 | 129 |
| 2023 Q2 | 43,637,466 | $435,668,849 | +$11,852,256 | $9.99 | 124 |
| 2023 Q1 | 42,478,076 | $376,567,538 | -$3,101,624 | $8.88 | 121 |
| 2022 Q4 | 42,696,157 | $468,798,220 | +$2,144,188 | $10.98 | 119 |
| 2022 Q3 | 43,069,388 | $561,182,776 | -$38,324,545 | $13.03 | 114 |
| 2022 Q2 | 44,940,935 | $567,552,048 | +$55,435,115 | $12.67 | 100 |
| 2022 Q1 | 40,367,078 | $565,503,716 | -$19,332,926 | $14.01 | 111 |
| 2021 Q4 | 40,421,865 | $1,170,057,078 | +$25,875,537 | $28.95 | 121 |
| 2021 Q3 | 39,378,816 | $1,180,362,633 | -$11,970,711 | $29.96 | 110 |
| 2021 Q2 | 39,520,770 | $1,048,795,893 | -$66,662,023 | $26.53 | 103 |
| 2021 Q1 | 41,346,108 | $1,285,407,277 | +$254,357,641 | $31.09 | 99 |
| 2020 Q4 | 33,136,833 | $1,089,462,176 | +$26,868,033 | $32.88 | 67 |
| 2020 Q3 | 31,854,383 | $1,111,189,598 | +$1,111,189,598 | $34.91 | 64 |